Kuan et al. discovered in 2003 that the targeted absence of JNK3 could not only activate JNK activity by stress but also protect mice from brain damage caused by cerebral ischemia and hypoxia, indicating that JNK3 was a promising target for the development of neuroprotective therapeutics for stroke [3]. This evidence concerns the gene MAPK10 and stroke disorder.